- Home
- TVRD vs LXEO Comparison
TVRD vs LXEO Comparison
Compare TVRD & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- LXEO
- Stock Information
- Founded
- TVRD 2017
- LXEO 2017
- Country
- TVRD United States
- LXEO United States
- Employees
- TVRD N/A
- LXEO N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- LXEO
- Sector
- TVRD Health Care
- LXEO
- Exchange
- TVRD Nasdaq
- LXEO Nasdaq
- Market Cap
- TVRD 246.5M
- LXEO 257.0M
- IPO Year
- TVRD N/A
- LXEO 2023
- Fundamental
- Price
- TVRD $29.92
- LXEO $4.79
- Analyst Decision
- TVRD Strong Buy
- LXEO Strong Buy
- Analyst Count
- TVRD 5
- LXEO 7
- Target Price
- TVRD $59.20
- LXEO $15.29
- AVG Volume (30 Days)
- TVRD 23.2K
- LXEO 279.8K
- Earning Date
- TVRD 08-14-2025
- LXEO 08-14-2025
- Dividend Yield
- TVRD N/A
- LXEO N/A
- EPS Growth
- TVRD N/A
- LXEO N/A
- EPS
- TVRD N/A
- LXEO N/A
- Revenue
- TVRD N/A
- LXEO N/A
- Revenue This Year
- TVRD N/A
- LXEO N/A
- Revenue Next Year
- TVRD N/A
- LXEO N/A
- P/E Ratio
- TVRD N/A
- LXEO N/A
- Revenue Growth
- TVRD N/A
- LXEO N/A
- 52 Week Low
- TVRD $8.13
- LXEO $1.45
- 52 Week High
- TVRD $34.31
- LXEO $11.96
- Technical
- Relative Strength Index (RSI)
- TVRD 65.43
- LXEO 54.88
- Support Level
- TVRD $22.91
- LXEO $4.50
- Resistance Level
- TVRD $31.54
- LXEO $5.00
- Average True Range (ATR)
- TVRD 1.65
- LXEO 0.33
- MACD
- TVRD 0.61
- LXEO -0.02
- Stochastic Oscillator
- TVRD 81.28
- LXEO 58.76
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.